drugset / Trial / NCT01234025
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.
Timeline
- Start
- 2010-11
- Primary completion
- 2013-05
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ISIS EIF4E Rx | Unknown | 800 mg | Intravenous |
| Subject | ISIS EIF4E Rx | Unknown | 1000 mg | Intravenous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |